Stage 1 Testicular Cancer: Types, Treatment, and Relapse Risk

Stage 1 testicular cancer means the tumor is confined to the testicle itself, with no sign of spread to lymph nodes or distant organs. It is the most common presentation: roughly 85% of seminomas and about 60% of non-seminomas are caught at this stage. The five-year survival rate for adequately managed stage 1 disease approaches 100%, making it one of the most curable cancers in medicine. That near-perfect cure rate, though, does not mean decisions after diagnosis are simple. The real questions for most patients revolve around what happens next: which treatment path minimizes both relapse risk and long-term side effects, and how closely you need to be monitored going forward.

How Stage 1 Is Diagnosed

The process almost always begins with a painless lump or swelling in one testicle, though some people notice a dull ache or heaviness. An ultrasound confirms the presence of a mass, and blood tests check three tumor markers: human chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH). These markers play roles not just in initial diagnosis but also in staging, tracking treatment response, and long-term surveillance.¹

If a tumor is suspected, the standard next step is radical inguinal orchiectomy, which means removing the affected testicle through an incision in the groin rather than the scrotum. This approach is considered the gold standard because it allows surgeons to control the spermatic cord at its root and avoids disrupting the scrotal tissue, which could theoretically seed cancer cells into a different drainage pathway.² When scrotal violation does occur during surgery, the risk of local recurrence appears to increase mainly if residual tumor is found in the scrotum afterward.³

After surgery, CT scans of the chest, abdomen, and pelvis confirm whether the cancer has spread. If imaging is clean and post-surgery marker levels normalize, the cancer is classified as clinical stage I.

Seminoma Versus Non-Seminoma

Testicular germ cell tumors fall into two broad camps, and the distinction matters because it drives almost every treatment decision that follows. About 55% to 60% of testicular cancers are pure seminomas, while 40% to 45% are non-seminomas.⁴ Seminomas tend to grow more slowly, which is why such a large share are caught at stage 1. Non-seminomas include several subtypes, the most clinically relevant being embryonal carcinoma, which is associated with a higher risk of hidden spread even when scans look normal.

On imaging, the two types also look different. MRI studies show that seminomas usually appear as solid nodular masses without hemorrhage or cystic areas, while non-seminomas more often have a capsule, mixed signals, and signs of internal bleeding or cyst formation.⁵ In practice, though, the definitive classification comes from pathology after the testicle is removed, not from imaging alone.

What Predicts Relapse in Stage 1 Seminoma

Even though stage 1 seminoma has an excellent prognosis, about 15% to 20% of patients on surveillance will eventually relapse. The question researchers have tried to answer for decades is whether features of the original tumor can reliably identify which patients are at higher risk. Two factors have emerged: tumor size and invasion of the rete testis, a network of channels inside the testicle where sperm collect before entering the epididymis.

A pooled analysis found that tumors larger than 4 cm had roughly double the risk of relapse compared with smaller tumors, and rete testis invasion carried a hazard ratio of about 1.7.⁶ A later systematic review confirmed these associations but cautioned that even among patients with both risk factors, most are still cured by orchiectomy alone and never relapse. The review also noted that the evidence supporting a strict 4 cm cutoff is limited and that using these factors to make routine clinical decisions warrants caution.⁷

What Predicts Relapse in Stage 1 Non-Seminoma

For non-seminomas, the single most powerful predictor is lymphovascular invasion (LVI), meaning tumor cells are found inside blood or lymph vessels within the orchiectomy specimen. A systematic review found that no other factor matched its prognostic value, particularly when pathologists used immunohistochemistry staining to identify vessel involvement rather than relying solely on standard staining.⁸ When vascular invasion was confirmed, it independently predicted relapse with a hazard ratio above 3 in one study.⁹

The presence of embryonal carcinoma serves as a secondary predictor, and a large population-based study added tumor invasion into the hilar soft tissue and tumor size to the list of independent relapse predictors for non-seminomas.¹⁰ In clinical practice, LVI status is the main factor guiding whether a patient is considered low or high risk.

Treatment Options After Orchiectomy

Across both tumor types, the overall cure rate for clinical stage 1 disease is about 99%, and this has been achievable through several different strategies for over two decades.¹¹ The challenge is not curing the disease but picking the approach that does so with the fewest consequences for your future health.

Stage 1 Seminoma

Three main strategies exist: active surveillance, adjuvant radiotherapy, and adjuvant chemotherapy with a single dose of carboplatin. Active surveillance means no additional treatment after orchiectomy; instead, you undergo regular imaging and blood work on a defined schedule, and treatment begins only if the cancer comes back. A randomized trial comparing radiotherapy to single-dose carboplatin found nearly identical relapse-free survival rates at five years, around 95% for carboplatin and 96% for radiotherapy.¹² Patients who received carboplatin felt less fatigued and missed fewer days of work.¹³

An interesting finding from that same trial was the rate of new cancers in the opposite testicle. Patients who received radiotherapy developed a second testicular cancer about four times more often than those given carboplatin, suggesting carboplatin may have a protective effect on the remaining testicle.¹⁴ For this reason, adjuvant radiotherapy has largely fallen out of favor in many countries.

Active surveillance remains the preferred strategy for most patients in current guidelines, and its outcomes hold up even in resource-limited settings. One study from the Indian subcontinent showed a five-year relapse-free survival of about 95%, comparable to international benchmarks, despite less than half of surveillance patients strictly adhering to follow-up schedules.¹⁵ A cost-effectiveness analysis found that non-risk-adapted active surveillance (offering surveillance to all stage 1 seminoma patients regardless of risk factors) was both the cheapest and most effective option over a ten-year period.¹⁶

Stage 1 Non-Seminoma

The same three broad strategies apply, though the details differ. Surveillance is again the standard for low-risk patients (no lymphovascular invasion). For high-risk patients, the choice is typically between one or two cycles of BEP chemotherapy (bleomycin, etoposide, and cisplatin) or retroperitoneal lymph node dissection (RPLND), a surgery that removes the lymph nodes behind the abdomen where non-seminomas most commonly spread first. The cure rate across all three strategies is about 99%.¹⁷ Which strategy is best depends on the individual’s risk profile, tolerance for repeated imaging and anxiety during surveillance, and willingness to accept the side-effect profiles of chemotherapy or surgery.

The Surveillance Experience

Choosing surveillance does not mean doing nothing. It means signing up for years of scheduled CT scans, blood tests, and clinic visits. A typical protocol involves imaging every few months in the first two years, gradually spacing out over five or more years. The schedule is demanding, and adherence is a real challenge. One study found that only about half of patients maintained optimal adherence, while roughly 38% were lost to follow-up entirely.¹⁸ Factors linked to better adherence included being a nonsmoker, having a partner, and being diagnosed more recently, likely reflecting improvements in how surveillance programs are structured and communicated over time.

The psychological burden is worth taking seriously. Young men facing years of scans can develop significant anxiety around each appointment, sometimes called “scanxiety.” Despite this, most patients value face-to-face contact with their oncologist and are interested in using technology to access test results between visits. These findings suggest that surveillance programs could improve adherence and reduce anxiety through better digital integration without eliminating in-person care.

A New Blood Test on the Horizon

One of the frustrations of surveillance is that the traditional blood markers, hCG, AFP, and LDH, miss a lot of relapses. At the time of relapse, conventional markers are normal in about 62% of cases.¹⁹ This means imaging does most of the heavy lifting in detecting recurrence, which adds radiation exposure and cost.

A microRNA called miR-371a-3p is emerging as a far more accurate blood-based marker. Overall, it has a sensitivity around 90% and specificity above 90%, substantially outperforming the traditional trio.²⁰ A prospective study specifically evaluating this marker in stage 1 surveillance patients reported even better numbers: 100% sensitivity and about 96% specificity for detecting relapses, working equally well for both seminomas and non-seminomas.²¹ If validated in larger studies and adopted clinically, this test could reduce the number of CT scans patients need during surveillance, cutting radiation exposure and potentially easing the logistical burden that contributes to patients dropping out of follow-up.

Long-Term Health After Treatment

Because testicular cancer typically strikes young men, and because survival rates are so high, the long-term effects of treatment have an outsized impact on quality of life. A large survivorship study found that testicular cancer survivors had a 24% higher risk of developing late health effects more than five years after diagnosis compared with the general population. The overall rate of late effects was about 66 per 1,000 person-years, with higher risks for high cholesterol, infertility, and orchitis. Chemotherapy and retroperitoneal lymph node dissection were both associated with increased risk, and being obese at the time of diagnosis was the strongest individual predictor of long-term problems.²²

The catalog of potential late effects is broader than most patients expect. Beyond infertility and metabolic problems, survivors may face cardiovascular disease, second cancers, kidney damage, hearing loss, nerve damage in the hands and feet, and psychological difficulties including chronic anxiety.²³ This is one of the strongest arguments in favor of surveillance when it is a viable option: if you can avoid chemotherapy or radiotherapy and still achieve the same cure rate, you sidestep most of these late effects entirely.

Fertility Considerations

Fertility is a concern at every stage. Even before treatment, men with testicular cancer often have lower sperm counts than average. Orchiectomy itself causes hormonal shifts, with follicle-stimulating hormone and luteinizing hormone rising after surgery and testosterone dipping slightly.²⁴ In most cases the remaining testicle compensates adequately, but not always, and any additional treatment further threatens fertility. Cisplatin-based chemotherapy can cause prolonged or permanent drops in sperm production, and RPLND can disrupt the nerves responsible for ejaculation.

Sperm banking before orchiectomy is recommended for anyone who thinks they might want biological children in the future. There is some debate about whether banking before or after surgery produces better samples, and the timing may be driven by practical considerations. What matters most is that the conversation happens early, ideally before any procedure, rather than as an afterthought.

Disparities in Care

Stage 1 testicular cancer should be a straightforward success story, but outcomes are not distributed equally. Insurance status, race, and geographic location all influence cancer-related outcomes, even for a cancer with a 99% cure rate.²⁵ Patients without insurance may face delays in diagnosis. Those living far from specialized centers may not have easy access to high-volume surgeons or structured surveillance programs. When a cancer is this curable, every preventable death becomes harder to accept.

Risk Factors and Genetic Susceptibility

The strongest established risk factor for testicular cancer is cryptorchidism, a condition in which one or both testicles fail to descend into the scrotum during fetal development.²⁶ A personal history of testicular cancer in the other testicle and a family history of the disease in a father or brother also raise risk substantially. The genetic basis is increasingly understood. A transcriptome-wide association study recently identified 46 candidate susceptibility genes, including 7 at locations not previously implicated in testicular cancer risk, suggesting the genetic landscape is broader than earlier genome studies revealed.²⁷ For now, there is no routine genetic screening for testicular cancer, but the expanding list of risk genes may eventually enable more targeted surveillance for high-risk individuals.